Media headlines about Spark Therapeutics (NASDAQ:ONCE) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spark Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.3589085853648 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- FY2018 Earnings Forecast for Spark Therapeutics Inc (ONCE) Issued By SunTrust Banks (americanbankingnews.com)
- William Blair Equities Analysts Lower Earnings Estimates for Spark Therapeutics Inc (ONCE) (americanbankingnews.com)
- Raymond James Financial Reiterates $66.00 Price Target for Spark Therapeutics (ONCE) (americanbankingnews.com)
- Why This Gene Therapy Pioneer Crashed 29.8% in December (finance.yahoo.com)
- Spark Therapeutics Inc (ONCE) Forecasted to Post FY2022 Earnings of $7.91 Per Share (americanbankingnews.com)
Spark Therapeutics (ONCE) opened at $51.49 on Wednesday. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75. The firm has a market capitalization of $1,910.00 and a price-to-earnings ratio of -7.15.
ONCE has been the subject of several research analyst reports. Royal Bank of Canada initiated coverage on Spark Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $100.00 price objective for the company. SunTrust Banks reiterated a “buy” rating and issued a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a research report on Monday, September 25th. Goldman Sachs Group reiterated a “buy” rating and issued a $111.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $105.00 price objective (up previously from $94.00) on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Finally, Jefferies Group reiterated a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $76.03.
In other news, insider Daniel Faga sold 6,000 shares of the firm’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $79.95, for a total value of $479,700.00. Following the completion of the transaction, the insider now owns 6,000 shares in the company, valued at $479,700. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total value of $1,430,800.00. Following the completion of the transaction, the chief executive officer now owns 250,000 shares of the company’s stock, valued at approximately $17,885,000. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,309 shares of company stock valued at $4,621,085. Company insiders own 7.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics (ONCE) Earning Somewhat Positive Media Coverage, Analysis Finds” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/01/10/spark-therapeutics-once-earning-somewhat-positive-media-coverage-analysis-finds.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.